FGF2 translationally induced by hypoxia is involved in negative and positive feedback loops with HIF-1alpha.
BACKGROUND
Fibroblast growth factor 2 (FGF2) is a major angiogenic factor involved in angiogenesis and arteriogenesis, however the regulation of its expression during these processes is poorly documented. FGF2 mRNA contains an internal ribosome entry site (IRES), a translational regulator expected to allow mRNA expression during cellular stress.


RESULTS
In the present study, we have developed a skin ischemia model in transgenic mice expressing a reporter transgene under the control of the FGF2 IRES. The results reveal that FGF2 is induced at the protein level during ischemia, concomitant with HIF-1alpha induction and a decrease in FGF2 mRNA. In addition, the FGF2 IRES is strongly activated under these ischemic conditions associated with hypoxia, whereas cap-dependent translation is repressed by 4E-BP hypophosphorylation. We also show that up-regulation of FGF2 protein expression in response to hypoxia correlates with the increase of FGF2 IRES activity in vitro, in human retinoblasts 911. The use of siRNAs targeting HIF or FGF2 indicates that FGF2 and HIF-1alpha reciprocally regulate their expression/accumulation, by a negative feedback loop in early hypoxia, followed by a positive feedback loop in late hypoxia.


CONCLUSIONS
FGF2 expression is up-regulated in vivo and in vitro in response to hypoxia. Strikingly, this up-regulation is not transcriptional. It seems to occur by an IRES-dependent mechanism, revealing new mechanistic aspects of the hypoxic response. In addition, our data show that FGF2 interacts with HIF-1alpha in a unique crosstalk, with distinct stages in early and late hypoxia. These data reveal the physiological importance of IRES-dependent translation during hypoxic stress and underline the complexity of the cellular response to hypoxia, suggesting a novel role of FGF2 in the regulation of HIF-1alpha during the induction of angiogenesis.
Conte
Caroline
C
Institut National de la Santé et de la Recherche Médicale (INSERM), U858, Toulouse, France.
Riant
Elodie
E
Toutain
Céline
C
Pujol
Françoise
F
Arnal
Jean-François
JF
Lenfant
Françoise
F
Prats
Anne-Catherine
AC
D000818:Animals; D015687:Cell Hypoxia; D039561:Eukaryotic Initiation Factor-4E / Q000502:physiology; D005246:Feedback; D016222:Fibroblast Growth Factor 2 / Q000235:genetics*; D005786:Gene Expression Regulation; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000502:physiology*; D008156:Luciferases / Q000235:genetics; D051379:Mice; D008822:Mice, Transgenic; D018919:Neovascularization, Physiologic; D014176:Protein Biosynthesis; D012270:Ribosomes / Q000378:metabolism; D012867:Skin / Q000098:blood supply; D016038:Skin Transplantation; D013524:Surgical Flaps
D039561:Eukaryotic Initiation Factor-4E; C497443:Hif1a protein, mouse; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D016222:Fibroblast Growth Factor 2; D008156:Luciferases